{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:43:41Z","timestamp":1790048621115,"version":"4.0.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41591-018-0200-x","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T10:56:10Z","timestamp":1538045770000},"page":"1732-1742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Structure-guided combination therapy to potently improve the function of mutant CFTRs"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-2696","authenticated-orcid":false,"given":"Guido","family":"Veit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Dreano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu G.","family":"Avramescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Bagdany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenore K.","family":"Beitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Lay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelin","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puiying A.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Ainscow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Orth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul","family":"Frenkiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Matouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely L.","family":"Lukacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"200_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","volume":"27","author":"G Veit","year":"2016","unstructured":"Veit, G. et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol. Biol. Cell 27, 424\u2013433 (2016).","journal-title":"Mol. Biol. Cell"},{"key":"200_CR2","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/ng.2745","volume":"45","author":"PR Sosnay","year":"2013","unstructured":"Sosnay, P. R. et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat. Genet. 45, 1160\u20131167 (2013).","journal-title":"Nat. Genet."},{"key":"200_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrg3849","volume":"16","author":"GR Cutting","year":"2015","unstructured":"Cutting, G. R. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat. Rev. Genet. 16, 45\u201356 (2015).","journal-title":"Nat. Rev. Genet."},{"key":"200_CR4","doi-asserted-by":"crossref","unstructured":"Liu, F., Zhang, Z., Csanady, L., Gadsby, D. C. & Chen, J. Molecular structure of the human CFTR ion channel. Cell 169, 85\u201395 e88 (2017).","DOI":"10.1016\/j.cell.2017.02.024"},{"key":"200_CR5","doi-asserted-by":"publisher","first-page":"a009514","DOI":"10.1101\/cshperspect.a009514","volume":"3","author":"JF Hunt","year":"2013","unstructured":"Hunt, J. F., Wang, C. & Ford, R. C. Cystic fibrosis transmembrane conductance regulator (ABCC7)structure. Cold Spring Harb. Perspect. Med. 3, a009514 (2013).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"200_CR6","doi-asserted-by":"publisher","first-page":"a009498","DOI":"10.1101\/cshperspect.a009498","volume":"3","author":"TC Hwang","year":"2013","unstructured":"Hwang, T. C. & Kirk, K. L. The CFTR ion channel: gating, regulation, and anion permeation. Cold Spring Harb. Perspect. Med. 3, a009498 (2013).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"200_CR7","first-page":"a009522","volume":"3","author":"PA Chong","year":"2013","unstructured":"Chong, P. A., Kota, P., Dokholyan, N. V. & Forman-Kay, J. D. Dynamics intrinsic to cystic fibrosis transmembrane conductance regulator function and stability. Cold Spring Harb. Perspect. Med. 3, a009522 (2013).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"200_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ceb.2011.04.012","volume":"23","author":"T Okiyoneda","year":"2011","unstructured":"Okiyoneda, T., Apaja, P. M. & Lukacs, G. L. Protein quality control at the plasma membrane. Curr. Opin. Cell Biol. 23, 483\u2013491 (2011).","journal-title":"Curr. Opin. Cell Biol."},{"key":"200_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.cell.2011.11.024","volume":"148","author":"WM Rabeh","year":"2012","unstructured":"Rabeh, W. M. et al. Correction of both NBD1 energetics and domain interface is required to restore \u0394F508 CFTR folding and function. Cell 148, 150\u2013163 (2012).","journal-title":"Cell"},{"key":"200_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cell.2011.11.023","volume":"148","author":"JL Mendoza","year":"2012","unstructured":"Mendoza, J. L. et al. Requirements for efficient correction of \u0394F508 CFTR revealed by analyses of evolved sequences. Cell 148, 164\u2013174 (2012).","journal-title":"Cell"},{"key":"200_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.chembiol.2013.06.004","volume":"20","author":"CM Farinha","year":"2013","unstructured":"Farinha, C. M. et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem. Biol. 20, 943\u2013955 (2013).","journal-title":"Chem. Biol."},{"key":"200_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jmb.2014.07.026","volume":"427","author":"L He","year":"2015","unstructured":"He, L. et al. Restoration of NBD1 thermal stability is necessary and sufficient to correct \u2206F508 CFTR folding and assembly. J. Mol. Biol. 427, 106\u2013120 (2015).","journal-title":"J. Mol. Biol."},{"key":"200_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/pro.2821","volume":"25","author":"JD Hall","year":"2016","unstructured":"Hall, J. D. et al. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy. Protein Sci. 25, 360\u2013373 (2016).","journal-title":"Protein Sci."},{"key":"200_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jmb.2006.10.086","volume":"365","author":"L Cui","year":"2007","unstructured":"Cui, L. et al. Domain interdependence in the biosynthetic assembly of CFTR. J. Mol. Biol. 365, 981\u2013994 (2007).","journal-title":"J. Mol. Biol."},{"key":"200_CR15","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1091\/mbc.e08-09-0950","volume":"20","author":"K Du","year":"2009","unstructured":"Du, K. & Lukacs, G. L. Cooperative assembly and misfolding of CFTR domains in vivo. Mol. Biol. Cell 20, 1903\u20131915 (2009).","journal-title":"Mol. Biol. Cell"},{"key":"200_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nsmb882","volume":"12","author":"K Du","year":"2005","unstructured":"Du, K., Sharma, M. & Lukacs, G. L. The \u0394F508 cystic fibrosis mutation impairs domain\u2013domain interactions and arrests post-translational folding of CFTR. Nat. Struct. Mol. Biol. 12, 17\u201325 (2005).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"200_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/nchembio.1253","volume":"9","author":"T Okiyoneda","year":"2013","unstructured":"Okiyoneda, T. et al. Mechanism-based corrector combination restores \u0394F508-CFTR folding and function. Nat. Chem. Biol. 9, 444\u2013454 (2013).","journal-title":"Nat. Chem. Biol."},{"key":"200_CR18","doi-asserted-by":"publisher","first-page":"14147","DOI":"10.1074\/jbc.M116.772335","volume":"292","author":"RM Vernon","year":"2017","unstructured":"Vernon, R. M. et al. Stabilization of a nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator yields insight into disease-causing mutations. J. Biol. Chem. 292, 14147\u201314164 (2017).","journal-title":"J. Biol. Chem."},{"key":"200_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1124\/mol.114.092478","volume":"86","author":"PW Phuan","year":"2014","unstructured":"Phuan, P. W. et al. Synergy-based small-molecule screen using a human lung epithelial cell line yields \u0394F508-CFTR correctors that augment VX-809 maximal efficacy. Mol. Pharmacol. 86, 42\u201351 (2014).","journal-title":"Mol. Pharmacol."},{"key":"200_CR20","doi-asserted-by":"publisher","first-page":"25636","DOI":"10.1074\/jbc.M115.671925","volume":"290","author":"M Lopes-Pacheco","year":"2015","unstructured":"Lopes-Pacheco, M. et al. Combination of correctors rescue \u0394F508-CFTR by reducing its association with Hsp40 and Hsp27. J. Biol. Chem. 290, 25636\u201325645 (2015).","journal-title":"J. Biol. Chem."},{"key":"200_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1042\/BJ20070478","volume":"406","author":"Y Wang","year":"2007","unstructured":"Wang, Y., Loo, T. W., Bartlett, M. C. & Clarke, D. M. Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochem. J. 406, 257\u2013263 (2007).","journal-title":"Biochem. J."},{"key":"200_CR22","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","volume":"377","author":"JL Taylor-Cousar","year":"2017","unstructured":"Taylor-Cousar, J. L. et al. Tezacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N. Engl. J. Med. 377, 2013\u20132023 (2017).","journal-title":"N. Engl. J. Med."},{"key":"200_CR23","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","volume":"108","author":"F Goor Van","year":"2011","unstructured":"Van Goor, F. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. USA 108, 18843\u201318848 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"200_CR24","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","volume":"24","author":"HY Ren","year":"2013","unstructured":"Ren, H. Y. et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol. Biol. Cell 24, 3016\u20133024 (2013).","journal-title":"Mol. Biol. Cell"},{"key":"200_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright, C. E. et al. Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N. Engl. J. Med. 373, 220\u2013231 (2015).","journal-title":"N. Engl. J. Med."},{"key":"200_CR26","doi-asserted-by":"publisher","first-page":"246ra97","DOI":"10.1126\/scitranslmed.3008889","volume":"6","author":"G Veit","year":"2014","unstructured":"Veit, G. et al. Some gating potentiators, including VX-770, diminish \u0394F508-CFTR functional expression. Sci. Transl. Med. 6, 246ra97 (2014).","journal-title":"Sci. Transl. Med."},{"key":"200_CR27","doi-asserted-by":"publisher","first-page":"246ra96","DOI":"10.1126\/scitranslmed.3008680","volume":"6","author":"DM Cholon","year":"2014","unstructured":"Cholon, D. M. et al. Potentiator ivacaftor abrogates pharmacological correction of \u0394F508 CFTR in cystic fibrosis. Sci. Transl. Med. 6, 246ra96 (2014).","journal-title":"Sci. Transl. Med."},{"key":"200_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00441-005-0062-7","volume":"323","author":"C Ehrhardt","year":"2006","unstructured":"Ehrhardt, C. et al. Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o-. Cell Tissue Res. 323, 405\u2013415 (2006).","journal-title":"Cell Tissue Res."},{"key":"200_CR29","doi-asserted-by":"publisher","first-page":"35825","DOI":"10.1074\/jbc.M110.131623","volume":"285","author":"PH Thibodeau","year":"2010","unstructured":"Thibodeau, P. H. et al. The cystic fibrosis\u2013causing mutation \u0394F508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J. Biol. Chem. 285, 35825\u201335835 (2010).","journal-title":"J. Biol. Chem."},{"key":"200_CR30","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1172\/JCI24898","volume":"115","author":"N Pedemonte","year":"2005","unstructured":"Pedemonte, N. et al. Small-molecule correctors of defective \u0394F508-CFTR cellular processing identified by high-throughput screening. J. Clin. Invest. 115, 2564\u20132571 (2005).","journal-title":"J. Clin. Invest."},{"key":"200_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.chembiol.2007.11.012","volume":"15","author":"LS Pissarra","year":"2008","unstructured":"Pissarra, L. S. et al. Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. Chem. Biol. 15, 62\u201369 (2008).","journal-title":"Chem. Biol."},{"key":"200_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1083\/jcb.201006012","volume":"191","author":"PM Apaja","year":"2010","unstructured":"Apaja, P. M., Xu, H. & Lukacs, G. L. Quality control for unfolded proteins at the plasma membrane. J. Cell Biol. 191, 553\u2013570 (2010).","journal-title":"J. Cell Biol."},{"key":"200_CR33","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1093\/hmg\/ddn269","volume":"17","author":"A Duarri","year":"2008","unstructured":"Duarri, A. et al. Molecular pathogenesis of megalencephalic leukoencephalopathy with subcortical cysts: mutations in MLC1 cause folding defects. Hum. Mol. Genet. 17, 3728\u20133739 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"200_CR34","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1074\/jbc.M111.268797","volume":"287","author":"K Takahashi","year":"2012","unstructured":"Takahashi, K. et al. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists. J. Biol. Chem. 287, 2099\u20132106 (2012).","journal-title":"J. Biol. Chem."},{"key":"200_CR35","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1091\/mbc.e13-07-0417","volume":"24","author":"PM Apaja","year":"2013","unstructured":"Apaja, P. M. et al. Ubiquitination-dependent quality control of hERG K+channel with acquired and inherited conformational defect at the plasma membrane. Mol. Biol. Cell 24, 3787\u20133804 (2013).","journal-title":"Mol. Biol. Cell"},{"key":"200_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nsb0398-180","volume":"5","author":"F Zhang","year":"1998","unstructured":"Zhang, F., Kartner, N. & Lukacs, G. L. Limited proteolysis as a probe for arrested conformational maturation of \u0394F508 CFTR. Nat. Struct. Biol. 5, 180\u2013183 (1998).","journal-title":"Nat. Struct. Biol."},{"key":"200_CR37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.bbamem.2006.03.006","volume":"1758","author":"T Hegedus","year":"2006","unstructured":"Hegedus, T. et al. F508del CFTR with two altered RXR motifs escapes from ER quality control but its channel activity is thermally sensitive. Biochim. Biophys. Acta 1758, 565\u2013572 (2006).","journal-title":"Biochim. Biophys. Acta"},{"key":"200_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00444-4","volume":"8","author":"M Bagdany","year":"2017","unstructured":"Bagdany, M. et al. Chaperones rescue the energetic landscape of mutant CFTR at single molecule and in cell. Nat. Commun. 8, 398 (2017).","journal-title":"Nat. Commun."},{"key":"200_CR39","doi-asserted-by":"publisher","first-page":"e1002462","DOI":"10.1371\/journal.pbio.1002462","volume":"14","author":"G Veit","year":"2016","unstructured":"Veit, G. et al. Ribosomal stalk protein silencing partially corrects the \u0394F508-CFTR functional expression defect. PLoS Biol. 14, e1002462 (2016).","journal-title":"PLoS Biol."},{"key":"200_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07504-1","volume":"7","author":"IM Pranke","year":"2017","unstructured":"Pranke, I. M. et al. Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. Sci. Rep. 7, 7375 (2017).","journal-title":"Sci. Rep."},{"key":"200_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nprot.2016.174","volume":"12","author":"X Liu","year":"2017","unstructured":"Liu, X. et al. Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nat. Protoc. 12, 439\u2013451 (2017).","journal-title":"Nat. Protoc."},{"key":"200_CR42","first-page":"50646","volume":"80","author":"L M\u00fcller","year":"2013","unstructured":"M\u00fcller, L., Brighton, L. E., Carson, J. L., Fischer, W. A. II & Jaspers, I. Culturing of human nasal epithelial cells at the air liquid interface. J. Vis. Exp. 80, 50646 (2013).","journal-title":"J. Vis. Exp."},{"key":"200_CR43","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1093\/hmg\/ddx367","volume":"26","author":"RG Avramescu","year":"2017","unstructured":"Avramescu, R. G. et al. Mutation-specific downregulation of CFTR2 variants by gating potentiators. Hum. Mol. Genet. 26, 4873\u20134885 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"200_CR44","doi-asserted-by":"publisher","first-page":"15370","DOI":"10.1073\/pnas.0706974104","volume":"104","author":"LS Ostedgaard","year":"2007","unstructured":"Ostedgaard, L. S. et al. Processing and function of CFTR-\u0394F508 are species-dependent. Proc. Natl. Acad. Sci. USA 104, 15370\u201315375 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"200_CR45","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1172\/JCI118917","volume":"98","author":"PJ French","year":"1996","unstructured":"French, P. J. et al. A \u0394F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. J. Clin. Invest. 98, 1304\u20131312 (1996).","journal-title":"J. Clin. Invest."},{"key":"200_CR46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.biocel.2016.10.001","volume":"80","author":"MF Cunha da","year":"2016","unstructured":"da Cunha, M. F. et al. Analysis of nasal potential in murine cystic fibrosis models. Int. J. Biochem. Cell Biol. 80, 87\u201397 (2016).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"200_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","volume":"13","author":"F Goor Van","year":"2014","unstructured":"Van Goor, F., Yu, H., Burton, B. & Hoffman, B. J. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cyst. Fibros. 13, 29\u201336 (2014).","journal-title":"J. Cyst. Fibros."},{"key":"200_CR48","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1124\/mol.109.062679","volume":"77","author":"R Robert","year":"2010","unstructured":"Robert, R. et al. Correction of the \u0394 phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol. Pharmacol. 77, 922\u2013930 (2010).","journal-title":"Mol. Pharmacol."},{"key":"200_CR49","doi-asserted-by":"publisher","first-page":"6729","DOI":"10.1021\/jm5007885","volume":"57","author":"KC Coffman","year":"2014","unstructured":"Coffman, K. C. et al. Constrained bithiazoles: small molecule correctors of defective \u0394F508-CFTR protein trafficking. J. Med. Chem. 57, 6729\u20136738 (2014).","journal-title":"J. Med. Chem."},{"key":"200_CR50","doi-asserted-by":"publisher","first-page":"a009761","DOI":"10.1101\/cshperspect.a009761","volume":"3","author":"SM Rowe","year":"2013","unstructured":"Rowe, S. M. & Verkman, A. S. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb. Perspect. Med. 3, a009761 (2013).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"200_CR51","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1039\/b924455g","volume":"2","author":"C Li","year":"2010","unstructured":"Li, C. & Naren, A. P. CFTR chloride channel in the apical compartments: spatiotemporal coupling to its interacting partners. Integr. Biol. (Camb) 2, 161\u2013177 (2010).","journal-title":"Integr. Biol. (Camb)"},{"key":"200_CR52","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1242\/jcs.089086","volume":"125","author":"S Monterisi","year":"2012","unstructured":"Monterisi, S. et al. CFTR regulation in human airway epithelial cells requires integrity of the actin cytoskeleton and compartmentalized cAMP and PKA activity. J. Cell Sci. 125, 1106\u20131117 (2012).","journal-title":"J. Cell Sci."},{"key":"200_CR53","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nature15729","volume":"528","author":"S Pankow","year":"2015","unstructured":"Pankow, S. et al. F508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature 528, 510\u2013516 (2015).","journal-title":"Nature"},{"key":"200_CR54","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1074\/mcp.M114.046375","volume":"14","author":"AM Trzci\u0144ska-Daneluti","year":"2015","unstructured":"Trzci\u0144ska-Daneluti, A. M. et al. RNA interference screen to identify kinases that suppress rescue of \u0394F508-CFTR. Mol. Cell. Proteomics 14, 1569\u20131583 (2015).","journal-title":"Mol. Cell. Proteomics"},{"key":"200_CR55","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.1191542","volume":"329","author":"T Okiyoneda","year":"2010","unstructured":"Okiyoneda, T. et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329, 805\u2013810 (2010).","journal-title":"Science"},{"key":"200_CR56","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/cdd.2016.22","volume":"23","author":"A Tosco","year":"2016","unstructured":"Tosco, A. et al. A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR. Cell Death Differ. 23, 1380\u20131393 (2016).","journal-title":"Cell Death Differ."},{"key":"200_CR57","doi-asserted-by":"publisher","first-page":"e1001998","DOI":"10.1371\/journal.pbio.1001998","volume":"12","author":"DM Roth","year":"2014","unstructured":"Roth, D. M. et al. Modulation of the maladaptive stress response to manage diseases of protein folding. PLoS Biol. 12, e1001998 (2014).","journal-title":"PLoS Biol."},{"key":"200_CR58","doi-asserted-by":"publisher","first-page":"e10365","DOI":"10.7554\/eLife.10365","volume":"4","author":"RN Hegde","year":"2015","unstructured":"Hegde, R. N. et al. Unravelling druggable signalling networks that control F508del-CFTR proteostasis. eLife 4, e10365 (2015).","journal-title":"eLife"},{"key":"200_CR59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nchembio.763","volume":"8","author":"B Calamini","year":"2011","unstructured":"Calamini, B. et al. Small-molecule proteostasis regulators for protein conformational diseases. Nat. Chem. Biol. 8, 185\u2013196 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"200_CR60","doi-asserted-by":"crossref","unstructured":"Griesenbach, U., Geddes, D. M. & Alton, E. W. The pathogenic consequences of a single mutated CFTR gene. Thorax 54 (Suppl 2), S19\u2013S23 (1999).","DOI":"10.1136\/thx.54.2008.S19"},{"key":"200_CR61","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1091\/mbc.e12-06-0424","volume":"23","author":"G Veit","year":"2012","unstructured":"Veit, G. et al. Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia. Mol. Biol. Cell 23, 4188\u20134202 (2012).","journal-title":"Mol. Biol. Cell"},{"key":"200_CR62","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","volume":"180","author":"X Liu","year":"2012","unstructured":"Liu, X. et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 180, 599\u2013607 (2012).","journal-title":"Am. J. Pathol."},{"key":"200_CR63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-1-61779-117-8_4","volume":"741","author":"T Neuberger","year":"2011","unstructured":"Neuberger, T., Burton, B., Clark, H. & Van Goor, F. Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators. Methods Mol. Biol. 741, 39\u201354 (2011).","journal-title":"Methods Mol. Biol."},{"key":"200_CR64","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1002\/j.1460-2075.1995.tb00119.x","volume":"14","author":"JH van Doorninck","year":"1995","unstructured":"van Doorninck, J. H. et al. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J. 14, 4403\u20134411 (1995).","journal-title":"EMBO J."},{"key":"200_CR65","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1096\/fj.10-160648","volume":"24","author":"W Namkung","year":"2010","unstructured":"Namkung, W., Thiagarajah, J. R., Phuan, P. W. & Verkman, A. S. Inhibition of Ca2+-activated Cl\u2013 channels by gallotannins as a possible molecular basis for health benefits of red wine and green tea. FASEB J. 24, 4178\u20134186 (2010).","journal-title":"FASEB J."},{"key":"200_CR66","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/(SICI)1099-1352(199909\/10)12:5<279::AID-JMR473>3.0.CO;2-3","volume":"12","author":"DG Myszka","year":"1999","unstructured":"Myszka, D. G. Improving biosensor analysis. J. Mol. Recognit. 12, 279\u2013284 (1999).","journal-title":"J. Mol. Recognit."},{"key":"200_CR67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0014-5793(98)00713-3","volume":"431","author":"AA Aleksandrov","year":"1998","unstructured":"Aleksandrov, A. A. & Riordan, J. R. Regulation of CFTR ion channel gating by MgATP. FEBS Lett. 431, 97\u2013101 (1998).","journal-title":"FEBS Lett."},{"key":"200_CR68","doi-asserted-by":"publisher","first-page":"e57317","DOI":"10.1371\/journal.pone.0057317","volume":"8","author":"EL Saussereau","year":"2013","unstructured":"Saussereau, E. L. et al. Characterization of nasal potential difference in cftr knockout and F508del-CFTR mice. PLoS One 8, e57317 (2013).","journal-title":"PLoS One"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0200-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0200-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-018-0200-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:57:26Z","timestamp":1684605446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-018-0200-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1038\/s41591-018-0200-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"assertion":[{"value":"28 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.L., W.L., K.M., S.G., P.A.M., F.J.K., E.A., A.J.O., P.M. and W.G.B. are employees of the Genomics Institute of the Novartis Research Foundation. I.S.-G. has been principal investigator in Vertex initiated clinical trials, received a Vertex Pharmaceuticals Innovation Award and served as a scientific advisory board member for Vertex Pharmaceuticals. G.L.L. is a member of the Scientific Advisory Board of Proteostasis Therapeutics Inc. All other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}